Early detection of pancreatic cancer in diabetics

糖尿病患者胰腺癌的早期发现

• 批准号: 9252236
• 负责人: Ru Chen
• 金额: $ 58.76万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-01 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9252236
• 关键词: Accounting; Adult; American; Area; Benign; Biological; Biological Assay; Biological Markers; Blood; Blood Screening; Blood Tests; Blood specimen; CA-19-9 Antigen; Cancer Etiology; Cancer Patient; Cancerous; Cessation of life; Clinical; Clinical Research; Cohort Studies; Collaborations; Data; Databases; Detection; Development; Diabetes Mellitus; Diagnosis; Disease; Early Diagnosis; Epidemic; Evaluation; Goals; High Prevalence; Hour; Hyperglycemia; Incidence; Institution; Intercept; Intervention; Investigation; Lead; Lesion; Link; Low Prevalence; Malignant Neoplasms; Malignant neoplasm of pancreas; Methods; Molecular; Non-Insulin-Dependent Diabetes Mellitus; Pancreas; Pancreatic Diseases; Pancreatic Ductal Adenocarcinoma; Patients; Plasma; Population; Premalignant; Preparation; Prevalence; Prognostic Marker; Proteins; Proteomics; Research Personnel; Resources; Risk; Sampling; Specificity; Specimen; Technology; Testing; Therapeutic Intervention; Time; Tissues; Translational Research; Triage; Tumor Tissue; Validation; base; biomarker development; biomarker panel; cancer biomarkers; candidate marker; case control; clinical application; cohort; cost effective; cost effectiveness; diabetic; diabetic patient; diagnostic biomarker; differential expression; effective therapy; experimental study; high risk population; mortality; multiple reaction monitoring; pancreatic juice; pancreatic neoplasm; pancreatic tumorigenesis; pre-clinical; proteomic signature; public health relevance; research study; screening; statistics; targeted imaging; tissue resource

DESCRIPTION (provided by applicant): Pancreatic cancer is a highly lethal disease that is very difficult to diagnose. The high mortality of this disease is predominantly due to the advanced stage of disease at the time of diagnosis and a lack of effective treatments. Due to the low prevalence of pancreatic cancer (0.01%), early detection would be most cost-effective in screening increased-risk populations, such as new-onset type-2 diabetics. Clinical and research studies have substantiated the link between pancreatic cancer and new-onset type-2 diabetes. Development of a highly accurate blood-based test to detect pancreatic cancer in this population would represent a breakthrough in early detection of pancreatic cancer. Such a blood test, if used on an annual basis in this higher-risk population, could serve as an effective and inexpensive method for initial targeted screening. In this project, we proposed to develop and characterize a blood-based proteomics signature that allows early detection of pancreatic cancer patients with new-onset diabetics. The Specific Aims are as follows: Specific Aim 1: unbiased global discovery of differential proteins associated with pancreatic cancer in the blood of diabetic patients using quantitative proteomics; Specific Aim 2: development of targeted proteomics assay for 35 selected biomarker candidates; Specific Aim 3: establishment of a proteomics signature (biomarker panel) for detecting early stage pancreatic cancer in diabetic patients; Specific Aim 4: evaluation of the proteomics signature in detecting pancreatic cancer in asymptomatic patients. This proposal builds on our decade-long systematic study of pancreatic tumorigenesis, the rich resource of previous discoveries in pancreatic cancer biomarker development, well-characterized study cohorts from different institutions, as well as cutting-edge proteomics platform technologies that we have developed and implemented. Successful development of a blood-based assay to facilitate the early detection of pancreatic cancer for diabetic patients would alleviate the current prolonged work-up of higher-risk populations and provide critically important interception opportunities to treat earlier stage cancer.

描述（由申请人提供）：胰腺癌是一种非常致命的疾病，很难诊断。这种疾病的高死亡率主要是由于诊断时疾病的晚期阶段和缺乏有效治疗的原因。由于胰腺癌的患病率低（0.01％），早期发现在筛查危险越高的人群（例如新发表2型糖尿病患者）方面将是最具成本效益的。临床和研究的研究证实了胰腺癌与2型糖尿病之间的联系。开发高度准确的血液测试以检测该人群中胰腺癌将代表早期发现胰腺癌的突破。这样的血液检查，如果在此高危人群中每年使用，则可以作为初始靶向筛查的有效且廉价的方法。在这个项目中，我们建议开发和表征血液基蛋白质组学的特征，该蛋白质组学特征可以尽早发现具有新发育糖尿病患者的胰腺癌患者。具体目的如下：特定目标1：使用定量蛋白质组学在糖尿病患者血液中与胰腺癌相关的差异蛋白的无偏全球发现；特定目的2：开发35个选定生物标志物候选者的靶向蛋白质组学测定法；特定目的3：建立用于检测糖尿病患者早期胰腺癌的蛋白质组学签名（生物标志物面板）；特定目标4：评估无症状患者胰腺癌的蛋白质组学特征。这项提案建立在我们长达十年的胰腺肿瘤发生系统的系统研究基础上，这是胰腺癌生物标志物发展的先前发现的丰富资源，来自不同机构的特征良好的研究队列，以及我们已经开发和实施的削减蛋白质组学平台技术。成功开发基于血液的测定法，以促进糖尿病患者早期发现胰腺癌的早期检测，这将减轻当前高风险人群的长期检查，并为治疗早期阶段癌症提供至关重要的拦截机会。